Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5498-5504

  Qian, Feng ^a   Villella, Jeannine ^a   Wallace, Paul K ^a   Mhawech Fauceglia, Paulette ^a   Tario Jr , Joseph D ^a   Andrews, Christopher ^a   Matsuzaki, Junko ^a   Valmori, Danila ^b   Ayyoub, Maha ^b   Frederick, Peter J ^a   Beck, Amy ^a   Liao, Jianqun ^a   Cheney, Richard ^a   Moysich, Kirsten ^a   Lele, Shashikant ^a   Shrikant, Protul ^a   Old, Lloyd J ^c   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Team 12   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; DEXTRO 1 METHYLTRYPTOPHAN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; N METHYLTRYPTOPHAN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; ASCITES; CANCER CELL; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DEGRADATION; DRUG EFFICACY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; NATURAL KILLER CELL; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TRYPTOPHAN METABOLISM;

CELL DIVISION; CELL LINE; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; OVARIAN NEOPLASMS; STEREOISOMERISM; T-LYMPHOCYTES; TRANSFECTION; TRYPTOPHAN;

EID: 67650422617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2106     Document Type: Article

References (26)

1. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3.
2. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24:242-8.
3. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
4. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
5. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-90.
6. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-61.
7. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51.
8. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9.
9. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
10. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
11. Grohmann U, Fallarino F, Bianchi R, et al. IL-6 inhibits the tolerogenic function of CD8 α+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol 2001;167:708-14.
12. Grohmann U, Fallarino F, Silla S, et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 2001;166:277-83.
13. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T-cell proliferation. J Immunol 2000;164:3596-9.
14. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72.
15. Mellor AL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003;171:1652-5.
16. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-5.
17. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7.
18. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111:2152-4.
19. Terness P, Chuang JJ, Bauer T, Jiga L, Opelz G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 2005;105:2480-6.
20. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-70.
21. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004;172:4100-10.
22. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069-77.
23. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
24. Austin CJ, Astelbauer F, Kosim-Satyaputra P, et al. Mouse and human indoleamine 2,3-dioxygenase display some distinct biochemical and structural properties. Amino Acids 2009;36:99-106.
25. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396:203-13.
26. Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153-7.